{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:02:56Z","timestamp":1792699376703,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-85398-0","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T11:12:12Z","timestamp":1742641932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["VRd vs. VPd as induction therapy in high risk newly diagnosed multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"given":"Chun Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Gui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu Sheng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"issue":"1","key":"85398_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L. et al. Cancer statistics, 2022. Cancer J. Clin. 72 (1), 7\u201333 (2022).","journal-title":"Cancer J. Clin."},{"issue":"1","key":"85398_CR2","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Primers. 3 (1), 17046 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"14","key":"85398_CR3","first-page":"1228","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael, J. et al. Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline. Clin. Oncol. 37 (14), 1228\u20131263 (2019).","journal-title":"Clin. Oncol."},{"issue":"24","key":"85398_CR4","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld, P. et al. Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group. Blood 127 (24), 2955\u20132962 (2016).","journal-title":"Blood"},{"issue":"3","key":"85398_CR5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32 (3), 309\u2013322 (2021).","journal-title":"Ann. Oncol."},{"issue":"1","key":"85398_CR6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1186\/s12885-022-09802-y","volume":"22","author":"WJ Fu","year":"2022","unstructured":"Fu, W. J. et al. Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial. BMC Cancer. 22 (1), 722 (2022).","journal-title":"BMC Cancer"},{"issue":"11","key":"85398_CR7","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26 (11), 2326\u20132335 (2012).","journal-title":"Leukemia"},{"issue":"1","key":"85398_CR8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-023-00816-8","volume":"13","author":"F Saj","year":"2023","unstructured":"Saj, F. et al. Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE phase II study. Blood Cancer. 13 (1), 45 (2023).","journal-title":"Blood Cancer"},{"issue":"8","key":"85398_CR9","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17 (8), e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"85398_CR10","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.clml.2017.02.018","volume":"17S","author":"NS Joseph","year":"2017","unstructured":"Joseph, N. S., Gentili, S., Kaufman, J. L., Lonial, S. & Nooka, A. K. High-risk multiple myeloma: Definition and management. Clin. Lymphoma Myeloma Leuk. 17S, S80\u2013S87 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"85398_CR11","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","volume":"115","author":"I Hanamura","year":"2022","unstructured":"Hanamura, I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int. J. Hematol. 115 (6), 762\u2013777 (2022).","journal-title":"Int. J. Hematol."},{"issue":"14","key":"85398_CR12","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal, M. et al. Lenalidomide, Bortezomib, and dexamethasone with transplantation for Myeloma. N. Engl. J. Med. 376 (14), 1311\u20131320 (2017).","journal-title":"N Engl. J. Med."},{"issue":"16","key":"85398_CR13","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","volume":"134","author":"L Rosi\u00f1ol","year":"2019","unstructured":"Rosi\u00f1ol, L. et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood 134 (16), 1337\u20131345 (2019).","journal-title":"Blood"},{"issue":"7","key":"85398_CR14","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41409-022-01697-4","volume":"57","author":"MR Gaballa","year":"2022","unstructured":"Gaballa, M. R. et al. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transpl. 57 (7), 1142\u20131149 (2022).","journal-title":"Bone Marrow Transpl."},{"key":"85398_CR15","unstructured":"Li, C. C., Zhang, W. Y. & Zhang, R. J. Early Efficacy Observation of Pomalidomide-based Regimen in the treatment of high-risk multiple myeloma. Zhongguo Shi Yan xue ye xue Za Zhi. 31(5):1432\u20131436. (2023)."},{"issue":"8","key":"85398_CR16","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/1078-0432.CCR-11-0498","volume":"18","author":"AA Chanan-Khan","year":"2012","unstructured":"Chanan-Khan, A. A., San Miguel, J. F., Jagannath, S., Ludwig, H. & Dimopoulos, M. A. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin. Cancer Res. 18 (8), 2145\u20132163 (2012).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"85398_CR17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-012-2040-6","volume":"71","author":"M Hoffmann","year":"2013","unstructured":"Hoffmann, M. et al. Absorption, metabolism and excretion of [14\u00a0C]pomalidomide in humans following oral administration. Cancer Chemother. Pharmacol. 71 (2), 489\u2013501 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"85398_CR18","doi-asserted-by":"crossref","first-page":"204062072210900","DOI":"10.1177\/20406207221090089","volume":"13","author":"D Fotiou","year":"2022","unstructured":"Fotiou, D., Gavriatopoulou, M., Terpos, E. & Dimopoulos, M. A. Pomalidomide- and dexamethasone-based regimens in the treatment of refractory\/relapsed multiple myeloma. Ther. Adv. Hematol. 13, 20406207221090089 (2022).","journal-title":"Ther. Adv. Hematol."},{"key":"85398_CR19","first-page":"1847","volume":"130","author":"P Sonneveld","year":"2017","unstructured":"Sonneveld, P. et al. MM-013 phase 2, Multicenter Study of Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) in patients (pts) with Relapsed\/Refractory multiple myeloma (RRMM) and renal impairment (RI): pharmacokinetics (PK) analysis. Blood 130, 1847 (2017).","journal-title":"Blood"},{"issue":"5","key":"85398_CR20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar, S. V. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am. J. Hematol. 95 (5), 548\u2013567 (2020).","journal-title":"Am. J. Hematol."},{"issue":"9","key":"85398_CR21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","volume":"11","author":"R Bansal","year":"2021","unstructured":"Bansal, R., Rakshit, S. & Kumar, S. Extramedullary disease in multiple myeloma. Blood Cancer J. 11 (9), 161 (2021).","journal-title":"Blood Cancer J."},{"issue":"10","key":"85398_CR22","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/bmt.2017.165","volume":"52","author":"L Kumar","year":"2017","unstructured":"Kumar, L. et al. Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome. Bone Marrow Transpl. 52 (10), 1473\u20131475 (2017).","journal-title":"Bone Marrow Transpl."},{"issue":"Supplement_1","key":"85398_CR23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2019-126160","volume":"134","author":"G Jackson","year":"2019","unstructured":"Jackson, G. et al. Outcomes of transplant-eligible newly diagnosed Ultra-high Risk Myeloma patients treated in the NCRI Myeloma XI Trial Indicate the need for early treatment stratification and Novel Treatment approaches. Blood 134 (Supplement_1), 604\u2013604 (2019).","journal-title":"Blood"},{"issue":"6","key":"85398_CR24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","volume":"25","author":"KD Short","year":"2011","unstructured":"Short, K. D. et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25 (6), 906\u2013908 (2011).","journal-title":"Leukemia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85398-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85398-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85398-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T11:12:39Z","timestamp":1742641959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85398-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["85398"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-85398-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9946"}}